Učitavanje...
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
BACKGROUND: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab....
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ https://ncbi.nlm.nih.gov/pubmed/21991949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0910383 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|